AstraZeneca confirms 1.55B voting rights outstanding

ASTRAZENECA PLC (AZN) reports its total voting rights as of 31 August 2026.

Rhea-AI Filing Summary

ASTRAZENECA PLC (AZN) reports its total voting rights as of 31 August 2026. The issued share capital with voting rights consists of 1,551,043,461 ordinary shares of US$0.25 each, and no shares are held in Treasury. Accordingly, the total number of voting rights is 1,551,043,461. Shareholders may use this figure as the denominator when calculating whether they must notify their interest, or any change in their interest, under the UK Financial Conduct Authority’s Disclosure and Transparency Rules.

Key Figures

Total voting rights: 1,551,043,461 voting rights Issued share capital with voting rights: 1,551,043,461 ordinary shares Nominal value per ordinary share: US$0.25 per ordinary share +1 more

4 metrics

Total voting rights 1,551,043,461 voting rights Total number of voting rights in AstraZeneca PLC as at 31 August 2026

Issued share capital with voting rights 1,551,043,461 ordinary shares Issued ordinary shares of US$0.25 with voting rights as at 31 August 2026

Nominal value per ordinary share US$0.25 per ordinary share Nominal value of AstraZeneca PLC ordinary shares

Treasury shares 0 shares Number of AstraZeneca PLC shares held in Treasury as at 31 August 2026

Key Terms

Total voting rights, issued share capital, Treasury, Disclosure and Transparency Rules, +1 more

5 terms

Total voting rights financial

"Therefore, the total number of voting rights in AstraZeneca PLC is 1,551,043,461."

The total voting rights number is the count of shares that carry the right to vote at a company’s shareholder meetings, reflecting how much voting power exists in the market. Investors use it to understand control and influence—like knowing how many votes are in play when measuring ownership stakes, calculating a shareholder’s voting percentage, or assessing how easy it would be for a holder to sway decisions.

issued share capital financial

"As at 31 August 2026 the issued share capital of AstraZeneca PLC with voting rights is 1,551,043,461 ordinary shares"

Issued share capital is the total value or number of a company's shares that have been created and given to investors, employees or others; think of it as the slices of a cake that have already been cut and distributed. It matters to investors because it determines ownership percentages, potential voting power and how future share sales can dilute existing holdings, affecting share value and control.

Treasury financial

"No shares are held in Treasury."

The treasury is the department or area within a government or organization responsible for managing its money, finances, and financial strategies. It handles tasks like collecting revenue, paying bills, and planning for future financial needs, much like a household manages its budget. For investors, understanding the treasury is important because it influences interest rates, government spending, and overall economic stability.

Disclosure and Transparency Rules regulatory

"The following notification is made in accordance with the Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1."

Rules that require companies to provide accurate, timely and complete information about their finances, operations, risks and governance to regulators, investors and the public. They matter to investors because consistent, clear reporting is like a reliable scoreboard: it makes it easier to compare companies, spot problems early, reduce surprises and fraud, and form better expectations about future performance and value.

voting rights financial

"Therefore, the total number of voting rights in AstraZeneca PLC is 1,551,043,461."

Voting rights are the ability of shareholders to have a say in important company decisions, like choosing leaders or approving big changes. They matter because they give owners a voice in how the company is run, similar to how voters influence elections, ensuring the company acts in shareholders’ interests.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the total number of voting rights in AstraZeneca PLC (AZN) as of 31 August 2026?

As of 31 August 2026, AstraZeneca PLC has 1,551,043,461 total voting rights, corresponding to its issued share capital of ordinary shares with voting rights and no shares held in Treasury.

How many ordinary shares with voting rights does AstraZeneca PLC (AZN) have issued?

AstraZeneca PLC has 1,551,043,461 ordinary shares of US$0.25 each issued with voting rights as of 31 August 2026.

Does AstraZeneca PLC (AZN) hold any Treasury shares as of 31 August 2026?

No. AstraZeneca PLC reports that no shares are held in Treasury as of 31 August 2026, so all issued ordinary shares carry voting rights.

How should AZN shareholders use the total voting rights figure?

Shareholders may use the 1,551,043,461 total voting rights figure as the denominator to determine whether they must notify their interest, or changes in their interest, under the Financial Conduct Authority's Disclosure and Transparency Rules.

What is the nominal value of AstraZeneca PLC (AZN) ordinary shares?

Each AstraZeneca PLC ordinary share has a nominal value of US$0.25, as stated for the 1,551,043,461 issued ordinary shares with voting rights.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 12:09 PM EDT Accepted by SEC EDGAR 09/01/2026 - 12:08 PM EDT Learn about SEC filing dates

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of September 2026 

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1. Total Voting Rights

1 September 2026

Total Voting Rights

The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 August 2026 the issued share capital of AstraZeneca PLC with voting rights is 1,551,043,461 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,551,043,461.

The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Matthew Bowden

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 01 September 2026

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary